红日药业：关于公司产品继续纳入国家医保药品目录的公告

Core Viewpoint - Hongri Pharmaceutical announced that its product, Xuebijing injection, will continue to be included in the new drug catalog for 2026-2027 under the current conditions as per the negotiation results released by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025 [2] Group 1 - The announcement confirms that Xuebijing injection will remain part of the updated drug catalog negotiations (Category B) [2] - The decision is based on the negotiations conducted by the National Healthcare Security Administration and the Ministry of Human Resources and Social Security [2]